Related Experiment Video

Updated: Aug 24, 2026

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
12:18

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment

Published on: January 11, 2020

Mild cognitive impairment: a nosological entity?

Thierry Voisin1, Jacques Touchon, Bruno Vellas

  • 1Department of Internal Medicine and Clinical Gerontology, Acute Unit for Alzheimer's Patients, Toulouse University, Toulouse, France. dintilhac.b@chu-toulouse.fr

Current Opinion in Neurology
|May 8, 2004
PubMed

Insights

Mild cognitive impairment (MCI) is a transitional stage between normal aging and dementia. Redefining MCI criteria is crucial for developing effective preventive therapies and understanding its link to Alzheimer's disease.

Area of Science:

  • Neurology
  • Gerontology
  • Cognitive Science

Background:

  • Mild cognitive impairment (MCI) represents a transitional phase between normal aging and dementia.
  • Current MCI criteria are not standardized, leading to heterogeneity in diagnosis and understanding.
  • MCI is considered a potential window for early intervention with preventive therapies.

Purpose of the Study:

  • To review the concept and evolving criteria of mild cognitive impairment.
  • To highlight the heterogeneity within MCI and its implications for diagnosis and treatment.
  • To emphasize the need for redefining MCI criteria for improved therapeutic development.

Main Methods:

  • Literature review of proposed and modified criteria for mild cognitive impairment.
  • Analysis of sources of heterogeneity in MCI, including biological, symptomatic, and clinical course factors.
  • Examination of proposed classifications for MCI subtypes.

Main Results:

  • Mild cognitive impairment is not a definitive diagnosis but an evolving concept.
  • Significant heterogeneity exists within MCI, complicating its role as an Alzheimer's disease predictor.
  • Proposed MCI classifications include amnestic, multiple-domain, and single non-memory subtypes.

Conclusions:

  • The heterogeneity of mild cognitive impairment necessitates a re-evaluation of diagnostic criteria.
  • Refined MCI criteria are essential for advancing the development of targeted preventive therapies.
  • Further research is needed to establish explicit diagnostic standards for MCI.

More Related Videos

The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease06:23

The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease

Published on: October 13, 2016

Evaluation of the Cognitive Performance of Hypertensive Patients with Silent Cerebrovascular Lesions07:30

Evaluation of the Cognitive Performance of Hypertensive Patients with Silent Cerebrovascular Lesions

Published on: April 23, 2021

Related Concept Videos

Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function. They...
Intellectual Disability01:29

Intellectual Disability

Intellectual disability (ID) is a neurodevelopmental condition characterized by deficits in intellectual and adaptive functioning that manifest during the developmental period. This condition encompasses challenges in reasoning, memory, problem-solving, and learning, accompanied by impairments in everyday life skills, such as communication, self-care, and social interactions. Intellectual disability affects approximately 1% of the population in the United States, impacting an estimated 5...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Dementia01:30

Dementia

Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.